Tylenol Autism & ADHD Lawsuits
Free, Confidential Case Review — No Fee Unless We Win
If you took Tylenol (acetaminophen) while pregnant and your child was later diagnosed with Autism Spectrum Disorder (ASD) or ADHD, Cornerstone Law wants to hear your story. Our attorneys are evaluating claims on behalf of families across the country who believe Johnson & Johnson, Kenvue, and retailers failed to warn about the drug’s potential neurodevelopmental risks
Why Families Are Filing Claims
For decades, acetaminophen — sold under the brand name Tylenol — has been marketed as the go-to pain and fever reliever for pregnant women, largely because alternatives like aspirin and ibuprofen carry their own pregnancy-related risks. But a growing body of research has raised concerns that prenatal acetaminophen exposure may be linked to a higher likelihood of autism and ADHD diagnoses in children.
Families who believe their child’s diagnosis is connected to acetaminophen use during pregnancy are pursuing legal claims against manufacturers and retailers for failing to adequately warn consumers.
What Is Tylenol / Acetaminophen?
Acetaminophen is an over-the-counter pain reliever and fever reducer found in Tylenol and hundreds of store-brand and generic products. It became the preferred choice for pregnant women after health authorities cautioned against aspirin use in pregnancy due to its association with Reye’s syndrome. Tylenol has been sold over the counter since 1960 and is currently manufactured by Kenvue, which spun off from Johnson & Johnson.
No Fees, Unless Recovery
Free Claim Review
We help you seek Justice & Compensation Due.
"*" indicates required fields
By submitting my request, I confirm that I have read and agree to the Privacy Statement and Terms of Service of this site and that I consent to receive emails, phone calls and/or text message offers and communications from Zeccola & Selinger LLC and at any telephone number or email address provided by me, including my wireless number if provided. I understand there may be a charge by my wireless carrier for such communications.I understand these communications may be generated using an autodialer and may contain pre-recorded messages and that consent is not required to utilize Consumer Help Center. I understand that this authorization overrides any previous registrations on a federal or state Do Not Call registry
The Science Behind the Lawsuits
Multiple research teams have examined a potential link between prenatal acetaminophen exposure and neurodevelopmental conditions in children, including:
- Early research (2008) exploring associations between childhood acetaminophen use and autism risk following vaccination.
- A large 2014 study published in JAMA Pediatrics, tracking tens of thousands of mother-child pairs, which found children exposed to acetaminophen in utero were more likely to show ADHD-like behaviors and receive an ADHD diagnosis by age seven — with the strongest association tied to extended use during pregnancy.
- A 2017 analysis raising the hypothesis that early acetaminophen exposure could contribute to autism through effects on brain development.
- A 2021 European study of more than 73,000 mother-child pairs, which reported meaningfully higher rates of autism and ADHD symptoms among children exposed to acetaminophen before birth.
The FDA has acknowledged that some of this research suggests a possible association, while also noting that acetaminophen remains considered the safer over-the-counter option during pregnancy compared to alternatives like ibuprofen. No study has definitively proven that acetaminophen causes autism or ADHD, and the science remains actively debated — which is precisely why the warning-label and failure-to-warn questions are now playing out in court.
Current Status of the Tylenol Litigation (Updated July 2026)
This litigation has moved through several major turns, and the legal landscape is still evolving:
- Thousands of Tylenol autism/ADHD cases were consolidated into a federal multidistrict litigation, MDL 3043, in the Southern District of New York.
- In 2023, the MDL judge excluded plaintiffs’ causation experts following a Daubert hearing, and in 2024 granted summary judgment largely ending the federal cases at that stage.
- Plaintiffs appealed to the Second Circuit Court of Appeals, which heard oral arguments in late 2025/early 2026.
- In September 2025, the Trump administration directed the FDA to notify physicians of a possible link between prenatal Tylenol use and autism/ADHD, and the FDA began the process of updating acetaminophen labeling.
- Kenvue updated Tylenol’s label in May 2026, though it did not include an autism-specific warning, and the FDA has not yet finalized any such label change.
- In a major development, on July 13, 2026, the Second Circuit revived more than 500 Tylenol autism and ADHD lawsuits, reversing the prior exclusion of plaintiffs’ expert testimony and reopening the door for these claims to move forward.
- New cases are also being filed directly in state courts, including in Pennsylvania, Florida, Illinois, and Texas (where a state attorney general’s claim against Tylenol has also survived a motion to dismiss).
Bottom line: After a period of setbacks, the litigation is regaining momentum, and both federal and state court options are actively developing. Statutes of limitations still apply, and they vary by state — which makes speaking with an attorney promptly important, even while the legal landscape continues to shift.